Due to a mistake on the publisher’s part, this article was originally published as a Systematic Review instead of Original Research.
The publisher apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
anlotinib, non-small cell lung cancer (NSCLC), bevacizumab, efficacy, safety
Citation
Frontiers Production Office (2022) Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab. Front. Pharmacol. 13:1092147. doi: 10.3389/fphar.2022.1092147
Received
07 November 2022
Accepted
07 November 2022
Published
22 November 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.